Nicox S.A. (LON:0RCQ)

Market Cap	20.64M
Revenue (ttm)	3.07M
Net Income (ttm)	-14.91M
Shares Out	n/a
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	260,436
Average Volume	78,840
Open	0.3740
Previous Close	0.3610
Day's Range	0.3740 - 0.4375
52-Week Range	0.1650 - 0.4375
Beta	0.89
RSI	60.86
Earnings Date	Jul 18, 2025

About Altus Power

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b ...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 28
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RCQ

Financial Performance

In 2022, Nicox's revenue was 3.27 million, a decrease of -54.78% compared to the previous year's 7.23 million. Losses were -27.76 million, -36.57% less than in 2021.